Results 11 to 20 of about 775,328 (297)

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

New England Journal of Medicine, 2018
M. Jongen‐Lavrencic, T. Grob, Diana Hanekamp, F. Kavelaars, A. A. Al Hinai, A. Zeilemaker, Claudia A. J. Erpelinck-Verschueren, P. Gradowska, R. Meijer, J. Cloos, B. Biemond, C. Graux, M. van Marwijk Kooy, M. Manz, T. Pabst, J. Passweg, V. Havelange, G. Ossenkoppele, M. Sanders, G. Schuurhuis, B. Löwenberg, P. Valk   +21 more
semanticscholar   +3 more sources

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Journal of Hematology & Oncology, 2021
The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of MRD results to make clinical decisions in MM
Joaquin Martinez-Lopez, Rafael Alonso, Sandy W. Wong, Rafael Rios, Nina Shah, Yanira Ruiz-Heredia, Jose Maria Sanchez-Pina, Ricardo Sanchez, Natasha Bahri, Irene Zamanillo, Maria Poza, Natalia Buenache, Cristina Encinas, Luis Juarez, Fatima Miras, Luis Collado, Santiago Barrio, Thomas Martin, Maria Teresa Cedena, Jeffrey Wolf   +19 more
doaj   +1 more source

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

Cancers, 2023
Simple Summary The assessment of responses is critical in patients diagnosed with multiple myeloma. Nowadays, one of the most informative parameters to discriminate responses to treatment and prognosis is minimal residual disease (MRD).
A. Medina-Herrera, M. Sarasquete, C. Jiménez, N. Puig, R. García-Sanz   +4 more
semanticscholar   +1 more source

Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.

Journal of Clinical Oncology, 2022
Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker with the potential to improve survival outcomes for non-small-cell lung cancer (NSCLC).
B. Pellini, A. Chaudhuri
semanticscholar   +1 more source

Advances in minimal residual disease monitoring in multiple myeloma

Critical reviews in clinical laboratory sciences, 2023
Multiple myeloma (MM) is characterized by the clonal expansion of plasma cells and the excretion of a monoclonal immunoglobulin (M-protein), or fragments thereof. This biomarker plays a key role in the diagnosis and monitoring of MM.
C. Wijnands, S. Noori, N. Donk, M. Vanduijn, J. Jacobs   +4 more
semanticscholar   +1 more source

Minimal residual disease [PDF]

Current Opinion in Hematology, 1999
Monitoring of residual disease in patients with malignant hematologic disorders has been recognized as an important diagnostic tool for assessment of the response to treatment and the individual risk of relapse. In a number of malignancies, employment of sensitive techniques permitting the identification of tumor cells within a 10(4)-fold or greater ...
openaire   +3 more sources

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

BMC Cancer, 2022
Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy.
Alexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste op Bruinink, Vincent van der Velden, Bronno van der Holt, Markus Hansson, Niels Frost Andersen, Ulf Christian Frølund, Carsten Helleberg, Fredrik H. Schjesvold, Lucia Ahlberg, Nina Gulbrandsen, Bjorn Andreasson, Birgitta Lauri, Einar Haukas, Julie Støve Bødker, Anne Stidsholt Roug, Martin Bøgsted, Marianne T. Severinsen, Henrik Gregersen, Niels Abildgaard, Pieter Sonneveld, Karen Dybkær   +26 more
doaj   +1 more source

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios

Frontiers in Oncology, 2022
Circulating-tumor DNA (ctDNA) has emerged as an important biomarker for monitoring disease status in cancer patients. Different ctDNA testing platforms have shown promising results in the early detection of disease, monitoring response to treatment, and ...
Karam Khaddour, Karam Khaddour, Alice Zhou, Omar H. Butt, Griffin Budde, Allyson Koyen Malashevich, George Ansstas   +6 more
doaj   +1 more source

Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma

British Journal of Cancer, 2022
Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global health. Cell-free circulating tumour DNA (ctDNA) is an emerging biomarker but has not been studied sufficiently in HNSCC.
S. Flach, K. Howarth, S. Hackinger, C. Pipinikas, Peter J. I. Ellis, K. McLay, G. Marsico, T. Forshew, C. Walz, C. Reichel, O. Gires, M. Canis, P. Baumeister   +12 more
semanticscholar   +1 more source

Minimal residual disease in multiple myeloma: current status

Biomarker Research, 2021
Multiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an independent prognostic factor of MM.
Hong Ding, Juan Xu, Zhimei Lin, Jingcao Huang, Fangfang Wang, Yan Yang, Yushan Cui, Hongmei Luo, Yuhan Gao, Xinyu Zhai, Weicui Pang, Li Zhang, Yuhuan Zheng   +12 more
doaj   +1 more source